Looks like "FSD Pharma Syndrome" Is Here At XORTX When XORTX was recently listed on the NASDAQ, their stock was as high as $6.00 to $7.00 a share.
Since then, their stock has fallen below $2.00 a share.
Obviously, XORTX didn't learn from HUGE's mistakes, and now they are becoming another FSD Pharma.
Keep it up, and XORTX will get delisted like FSD Pharma is about to face.